Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Merck
Pharma
FDA signs off on Merck’s potential blockbuster Winrevair for PAH
With the FDA’s approval of Winrevair to treat pulmonary arterial hypertension, Merck is set to launch the first disease-modifying treatment for PAH.
Kevin Dunleavy
Mar 26, 2024 5:11pm
FDA approves Johnson & Johnson's combo pill Opsynvi for PAH
Mar 25, 2024 11:05am
CDMO PharmaLogic expands deal with radiopharma specialist Ratio
Mar 18, 2024 9:27am
Merck's Keytruda improves survival in cervical cancer trial
Mar 15, 2024 11:31am
Merck challenges Johns Hopkins University's Keytruda patents
Mar 14, 2024 7:30am
CEOs from BMS, J&J and Merck defend high drug costs to senators
Feb 8, 2024 3:05pm